Callan Family Office LLC Lowers Holdings in Waters Corporation (NYSE:WAT)

Callan Family Office LLC decreased its holdings in Waters Corporation (NYSE:WAT) by 30.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 573 shares of the medical instruments supplier’s stock after selling 248 shares during the quarter. Callan Family Office LLC’s holdings in Waters were worth $211,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Lederer & Associates Investment Counsel CA lifted its stake in shares of Waters by 1.0% in the 1st quarter. Lederer & Associates Investment Counsel CA now owns 3,155 shares of the medical instruments supplier’s stock valued at $1,163,000 after purchasing an additional 30 shares in the last quarter. FourThought Financial Partners LLC lifted its stake in shares of Waters by 5.1% in the 1st quarter. FourThought Financial Partners LLC now owns 658 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 32 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in shares of Waters by 4.8% in the 4th quarter. Benjamin Edwards Inc. now owns 744 shares of the medical instruments supplier’s stock valued at $276,000 after purchasing an additional 34 shares in the last quarter. Claret Asset Management Corp lifted its stake in shares of Waters by 3.6% in the 4th quarter. Claret Asset Management Corp now owns 1,103 shares of the medical instruments supplier’s stock valued at $409,000 after purchasing an additional 38 shares in the last quarter. Finally, Lido Advisors LLC lifted its stake in shares of Waters by 2.2% in the 4th quarter. Lido Advisors LLC now owns 1,734 shares of the medical instruments supplier’s stock valued at $643,000 after purchasing an additional 38 shares in the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Price Performance

WAT stock opened at $291.63 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.75 and a debt-to-equity ratio of 0.55. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $423.56. The stock’s 50 day moving average is $319.45 and its two-hundred day moving average is $346.58. The company has a market capitalization of $17.36 billion, a PE ratio of 26.30, a P/E/G ratio of 2.74 and a beta of 1.04.

Waters (NYSE:WAT) last posted its quarterly earnings data on Monday, August 4th. The medical instruments supplier reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.02. Waters had a return on equity of 38.60% and a net margin of 21.71%. The company had revenue of $771.33 million for the quarter, compared to the consensus estimate of $745.96 million. During the same period in the previous year, the business earned $2.63 EPS. Waters’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts predict that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

WAT has been the topic of several research analyst reports. Jefferies Financial Group set a $385.00 price objective on Waters and gave the company a “buy” rating in a research note on Monday, August 4th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Waters and gave the stock a “hold” rating in a research report on Tuesday, August 5th. UBS Group reissued a “neutral” rating on shares of Waters in a research report on Tuesday, July 15th. Scotiabank reissued a “sector outperform” rating and set a $465.00 price target on shares of Waters in a research report on Friday, July 11th. Finally, Wall Street Zen lowered Waters from a “buy” rating to a “hold” rating in a research report on Saturday, July 26th. Ten analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Waters has an average rating of “Hold” and a consensus target price of $378.73.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.